drugset / Trial / NCT03859986
Study in Subjects With Moderate Atopic Dermatitis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis
Timeline
- Start
- 2019-03-08
- Primary completion
- 2020-01
- Completion
- 2020-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROVAZOLAC | Small molecule | 5 % | Topical |